Steering Committee Consultation Roadmap - Update

Review of Meetings

First meeting (June 25, 2018)

1. Background on Guidelines Reform
2. Objectives and guiding principles
3. Outline of proposed new Guidelines framework and associated suggested questions

Second - teleconference calls (August 15, 2018)

• Use of external price referencing
• Use of List and Net price ceilings
• Risk assessment and prioritization criteria for Category 1 and 2 drugs
• Re-benching criteria

Third Meeting- teleconference calls (September 12, 2018)

1. Tests for Category 1 drugs
2. Tests for Category 2 drugs
3. Use of confidential pricing information
4. Application of new regime to existing drugs

December 13, 2018 – face to face meeting

Case Studies

1. Large size market with therapeutic alternatives
2. Large size market with no therapeutic alternatives
3. Two indications with different market conditions
4. Second line oncology
5. Cure for large population
6. EDRD drug

Next Steps

• Final Report of Technical Working Group – Feb/2019
• PMPRB Solicit final written feedback from SC Feb/2019
  • Specific questions on each topic and on proposed framework overall
• PMPRB distribute draft SC Report to members 2 weeks prior to final meeting
• Final face-to-face meeting to review the draft report and finalize
• Final SC and TWG reports submitted to the Board
• Release Draft Guidelines for next phase of consultation post CG2